NewsMV
Substantially all planned clinical sites for the REO 033 study are now activated, with multiple patients currently enrolled in the randomized trial evaluating pelareorep in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer.
(Nasdaq: ONCY) stated it expects to have sufficient Part A data to provide an interim clinical update by year-end 2026.
The REO 033 study is a randomized controlled trial assessing pelareorep in combination with folinic acid, fluorouracil, irinotecan, and bevacizumab against the same chemotherapy regimen without pelareorep.
Part A is designed to enroll approximately 60 patients randomized between the two treatment arms.
Keep reading